Travere Therapeutics

Bewertungs-Analyse

Über das Unternehmen

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in th

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Travere Therapeutics kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.